Rodolphe Thiebaut

List of Publications by Year
in descending order

211 papers	14,774 citations	30070 54 h-index	20358 116 g-index
230 all docs	230 docs citations	230 times ranked	15564 citing authors

#	Article	IF	Citations
1	Doubly robust evaluation of high-dimensional surrogate markers. Biostatistics, 2023, 24, 985-999.	1.5	0
2	mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional $\alpha\beta$ and $\gamma\delta$ T cells in Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2022, 33, 121-137.	6.1	22
3	Methodological guidelines to estimate population-based health indicators using linked data and/or machine learning techniques. Archives of Public Health, 2022, 80, 9.	2.4	3
4	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Medicine, 2022, 19, e1003865.	8.4	27
5	Within-host models of SARS-CoV-2: What can it teach us on the biological factors driving virus pathogenesis and transmission?. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101055.	1.4	6
6	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. EBioMedicine, 2022, 80, 104062.	6.1	10
7	NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. Vaccines, 2022, 10, 884.	4.4	1
8	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. Journal of Immunology, 2022, 208, 2663-2674.	0.8	8
9	Random forests for high-dimensional longitudinal data. Statistical Methods in Medical Research, 2021, 30, 166-184.	1.5	44
10	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2021, 21, 493-506.	9.1	115
11	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. AIDS Research and Human Retroviruses, 2021, 37, 214-223.	1.1	3
12	Health Care Students' Knowledge of and Attitudes, Beliefs, and Practices Toward the French COVID-19 App: Cross-sectional Questionnaire Study. Journal of Medical Internet Research, 2021, 23, e26399.	4.3	31
13	Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data. Nature Communications, 2021, 12, 4385.	12.8	29
14	Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines. Statistical Methods in Medical Research, 2021, 30, 2130-2147.	1.5	0
15	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nature Communications, 2021, 12, 5215.	12.8	22
16	Evolution of body composition following successful kidney transplantation is strongly influenced by physical activity: results of the CORPOS study. BMC Nephrology, 2021, 22, 31.	1.8	5
17	Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity. Covid, 2021, 1, 472-488.	1.5	6
18	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Medicine, 2021, 18, e1003813.	8.4	34

#	Article	IF	Citations
19	Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect. Journal of Immunological Methods, 2020, 477, 112711.	1.4	2
20	Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nature Communications, 2020, 11, 3730.	12.8	33
21	Conventional Dendritic Cells and Slan+ Monocytes During HIV-2 Infection. Frontiers in Immunology, 2020, 11, 1658.	4.8	2
22	Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome. Journal of Clinical Immunology, 2020, 40, 1082-1092.	3.8	48
23	A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus. Journal of Theoretical Biology, 2020, 495, 110254.	1.7	13
24	dearseq: a variance component score test for RNA-seq differential analysis that effectively controls the false discovery rate. NAR Genomics and Bioinformatics, 2020, 2, lqaa093.	3.2	18
25	Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV. Journal of Infectious Diseases, 2019, 219, 89-100.	4.0	11
26	Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation. Journal of Virology, 2019, 93, .	3.4	26
27	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV,the, 2019, 6, e334-e340.	4.7	5
28	Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals. Frontiers in Immunology, 2019, 10, 874.	4.8	11
29	Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection. PLoS Pathogens, 2019, 15, e1007758.	4.7	8
30	HIV Controllers Have Low Inflammation Associated with a Strong HIV-Specific Immune Response in Blood. Journal of Virology, 2019, 93, .	3.4	24
31	Effects of a physical activity programme to prevent physical performance decline in oncoâ€geriatric patients: a randomized multicentre trial. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 287-297.	7.3	38
32	Sequential Dirichlet process mixtures of multivariate skew t-distributions for model-based clustering of flow cytometry data. Annals of Applied Statistics, 2019, 13, .	1.1	14
33	New insights are game-changers in HIV-2 disease management. Lancet HIV,the, 2019, 6, e214.	4.7	1
34	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	3.0	7
35	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1â€"Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 292-300.	2.1	24
36	Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. Aids, 2019, 33, 279-284.	2.2	19

#	Article	IF	Citations
37	B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape. Aids, 2019, 33, 23-32.	2.2	12
38	Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts. Statistics in Medicine, 2019, 38, 221-235.	1.6	3
39	Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. Journal of Clinical Investigation, 2019, 129, 1960-1971.	8.2	41
40	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	4.7	187
41	Visualizing omics and clinical data: Which challenges for dealing with their variety?. Methods, 2018, 132, 3-18.	3.8	7
42	Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors. BMC Medical Research Methodology, 2018, 18, 159.	3.1	6
43	A new method for evaluating the impacts of semantic similarity measures on the annotation of gene sets. PLoS ONE, 2018, 13, e0208037.	2.5	3
44	HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. PLoS ONE, 2018, 13, e0207794.	2.5	11
45	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	3.0	34
46	cytometree: A binary tree algorithm for automatic gating in cytometry analysis. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 1132-1140.	1.5	21
47	Controlling IL-7 Injections in HIV-Infected Patients. Bulletin of Mathematical Biology, 2018, 80, 2349-2377.	1.9	5
48	Prenatal therapy with pyrimethamineÂ+ sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. American Journal of Obstetrics and Gynecology, 2018, 219, 386.e1-386.e9.	1.3	64
49	Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet, The, 2018, 392, 787-790.	13.7	103
50	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. International Journal of Infectious Diseases, 2018, 74, 83-96.	3.3	21
51	Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France. PLoS ONE, 2018, 13, e0193300.	2.5	33
52	Sparse partial least squares with group and subgroup structure. Statistics in Medicine, 2018, 37, 3338-3356.	1.6	9
53	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, 2017, 20, 2251-2261.	6.4	107
54	Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aids, 2017, 31, 2355-2365.	2.2	4

#	Article	IF	Citations
55	Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatric Blood and Cancer, 2017, 64, e26683.	1.5	27
56	Modeling $\mathrm{CD4}^{+}$ T cells dynamics in HIV-infected patients receiving repeated cycles of exogenous Interleukin 7. Annals of Applied Statistics, 2017, 11, .	1.1	7
57	Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. Biometrics, 2017, 73, 294-304.	1.4	8
58	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	3.0	17
59	Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. PLoS ONE, 2017, 12, e0169164.	2.5	5
60	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	3.0	5
61	No compensatory lung growth after resection in a one-year follow-up cohort of patients with lung cancer. Journal of Thoracic Disease, 2017, 9, 3938-3945.	1.4	4
62	Group and sparse group partial least square approaches applied in genomics context. Bioinformatics, 2016, 32, 35-42.	4.1	50
63	Immunologic response in treatmentâ€naÃ¯ve HIVâ€2â€infected patients: the IeDEA West Africa cohort. Journal of the International AIDS Society, 2016, 19, 20044.	3.0	13
64	Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study. PLoS ONE, 2016, 11, e0161594.	2.5	55
65	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. Journal of Virology, 2016, 90, 5315-5328.	3.4	12
66	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
67	Reply to Bordoni et al. Clinical Infectious Diseases, 2016, 63, 1684-1685.	5.8	0
68	Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2â€"Infected Controllers. Journal of Immunology, 2016, 197, 2787-2795.	0.8	19
69	Optimization and evaluation of Luminex performance with supernatants of antigen-stimulated peripheral blood mononuclear cells. BMC Immunology, 2016, 17, 44.	2.2	10
70	Surveillance of Î³Î´ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants. Journal of the American Society of Nephrology: JASN, 2016, 27, 637-645.	6.1	41
71	Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clinical Infectious Diseases, 2016, 62, 1178-1185.	5.8	59
72	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	3.0	4

#	Article	IF	Citations
73	Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002107.	8.4	135
74	Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS ONE, 2016, 11, e0152952.	2.5	4
75	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS ONE, 2016, 11, e0153484.	2.5	20
76	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. PLoS ONE, 2016, 11, e0168640.	2.5	8
77	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology, 2015, 27, 1.	2.7	6
78	Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. Aids, 2015, 29, 2099-2108.	2.2	47
79	Dose finding with longitudinal data: simpler models, richer outcomes. Statistics in Medicine, 2015, 34, 2983-2998.	1.6	13
80	Time-Course Gene Set Analysis for Longitudinal Gene Expression Data. PLoS Computational Biology, 2015, 11, e1004310.	3.2	60
81	Recent developments in clinical trial designs for HIV vaccine research. Human Vaccines and Immunotherapeutics, 2015, 11, 1022-1029.	3.3	7
82	Decreased HIV-Specific T-Regulatory Responses Are Associated with Effective DC-Vaccine Induced Immunity. PLoS Pathogens, 2015, 11, e1004752.	4.7	23
83	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. International Journal of Epidemiology, 2015, 44, 251-263.	1.9	10
84	Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. Neurology, 2015, 85, 1065-1073.	1.1	23
85	Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. Alzheimer's and Dementia, 2015, 11, 1098-1109.	0.8	169
86	Parameters identification for a model of T cell homeostasis. Mathematical Biosciences and Engineering, 2015, 12, 917-936.	1.9	0
87	Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4+T Cells in HIV-1 Infection. PLoS Computational Biology, 2014, 10, e1003630.	3.2	20
88	Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. European Journal of Immunology, 2014, 44, 2802-2810.	2.9	102
89	Microbicide-vaccine Combination Provides Significant Protection against Vaginal SHIV-162P3 Challenge in Cynomolgous Monkeys. AIDS Research and Human Retroviruses, 2014, 30, A26-A26.	1.1	0
90	T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults. BMC Immunology, 2014, 15, 13.	2.2	6

#	Article	IF	Citations
91	Reproducibility issues in science, is *P* value really the only answer?. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1934.	7.1	14
92	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV,the, 2014, 1, e119-e126.	4.7	32
93	Vaccines for Therapeutic Cellular Immunity that Target HIV Gag, Pol and Nef Epitopes to CD40 and DCIR Elicit T-cell Responses in Rhesus Macaques. AIDS Research and Human Retroviruses, 2014, 30, A245-A245.	1.1	1
94	Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 869-874.	7.1	542
95	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	5.8	140
96	Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials, 2014, 15, 68.	1.6	11
97	Body composition in 98 patients awaiting kidney transplantation. Nutrition, 2014, 30, 186-191.	2.4	4
98	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. HIV Clinical Trials, 2014, 15, 185-198.	2.0	6
99	An Evaluation of HIV Elite Controller Definitions within a Large Seroconverter Cohort Collaboration. PLoS ONE, 2014, 9, e86719.	2.5	80
100	NIMROD: A program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations. Computer Methods and Programs in Biomedicine, 2013, 111, 447-458.	4.7	18
101	Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?. Aids, 2013, 27, 1362-1365.	2.2	2
102	Discussion on the effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults. Aids, 2013, 27, 146-147.	2.2	0
103	Mathematical modelling of HIV prevention intervention. Aids, 2013, 27, 475-476.	2.2	5
104	Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort. Journal of Infectious Diseases, 2013, 207, 622-627.	4.0	61
105	Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study. PLoS Medicine, 2013, 10, e1001542.	8.4	71
106	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7
107	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	5.8	92
108	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	5.8	88

#	Article	IF	Citations
109	Dose‐finding design using mixed‐effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Statistics in Medicine, 2013, 32, 5430-5447.	1.6	26
110	Clonally Diverse T Cell Homeostasis Is Maintained by a Common Program of Cell-Cycle Control. Journal of Immunology, 2013, 190, 3985-3993.	0.8	35
111	Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. Aids, 2013, 27, 1421-1431.	2.2	16
112	Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study. PLoS ONE, 2013, 8, e66135.	2.5	32
113	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. PLoS ONE, 2013, 8, e71174.	2.5	12
114	Reconnaître la spécificité de la recherche en santé publique pour améliorer son impact scientifique, sanitaire et sociétal. Sante Publique, 2013, Vol. 24, 383-385.	0.1	3
115	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	1.9	34
116	Maximum a Posteriori Estimation in Dynamical Models of Primary HIV Infection. Statistical Communications in Infectious Diseases, 2012, 4, .	0.2	8
117	Initiation of c-ART in HIV-1 Infected Patients Is Associated With a Decrease of the Metabolic Activity of the Thymus Evaluated Using FDG-PET/Computed Tomography. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 56-63.	2.1	15
118	Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. Aids, 2012, 26, 951-957.	2.2	36
119	Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. Aids, 2012, 26, 711-720.	2.2	20
120	Treatment Monitoring of HIV‐Infected Patients based on Mechanistic Models. Biometrics, 2012, 68, 902-911.	1.4	20
121	Association of Soluble CD14 and Inflammatory Biomarkers With HIV-2 Disease Progression. Clinical Infectious Diseases, 2012, 55, 1417-1425.	5.8	24
122	A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics, 2012, 13, 325.	2.6	129
123	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	2.9	7
124	CMV plasma DNAemia and risk of cancer among HIV-infected patients: A case–control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002–2007. Journal of Clinical Virology, 2011, 50, 177-180.	3.1	0
125	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	9.1	345
126	Joint Modeling of the Clinical Progression and of the Biomarkers' Dynamics Using a Mechanistic Model. Biometrics, 2011, 67, 59-66.	1.4	9

#	Article	IF	Citations
127	Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure. JAMA - Journal of the American Medical Association, 2011, 305, 1327.	7.4	315
128	Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. Cmaj, 2011, 183, E115-E127.	2.0	202
129	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	5.8	180
130	Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. Aids, 2011, 25, 865-867.	2.2	38
131	Quantification of the Relative Importance of CTL, B Cell, NK Cell, and Target Cell Limitation in the Control of Primary SIV-Infection. PLoS Computational Biology, 2011, 7, e1001103.	3.2	23
132	Universal Definition of Loss to Follow-Up in HIV Treatment Programs: A Statistical Analysis of 111 Facilities in Africa, Asia, and Latin America. PLoS Medicine, 2011, 8, e1001111.	8.4	167
133	Heterogeneous viral environment in a HIV spatial model. Discrete and Continuous Dynamical Systems - Series B, 2011, 15, 545-572.	0.9	18
134	First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. Aids, 2010, 24, 1043-1050.	2.2	31
135	Comparison of Early CD4 T-Cell Count in HIV-1 Seroconverters in CÃ´te d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 260-265.	2.1	10
136	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Aids, 2010, 24, 1537-1548.	2.2	381
137	Score Tests for Exploring Complex Models: Application to HIV Dynamics Models. Biometrical Journal, 2010, 52, 10-21.	1.0	7
138	Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. Journal of Antimicrobial Chemotherapy, 2010, 65, 434-437.	3.0	22
139	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	2.8	309
140	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical Trials, 2010, 7, 19-35.	1.6	33
141	On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate patients too. Journal of Clinical Epidemiology, 2010, 63, 342-343.	5.0	4
142	Difference in Absolute CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. Journal of AIDS & Clinical Research, 2010, 01, 1-4.	0.5	27
143	Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 299-304.	1.6	9
144	Enhanced T cell recovery in HIV-1â€"infected adults through IL-7 treatment. Journal of Clinical Investigation, 2009, 119, 997-1007.	8.2	288

#	Article	IF	Citations
145	Quantifying Thymic Export: Combining Models of Naive T Cell Proliferation and TCR Excision Circle Dynamics Gives an Explicit Measure of Thymic Output. Journal of Immunology, 2009, 183, 4329-4336.	0.8	110
146	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. Diabetes Care, 2009, 32, 474-480.	8.6	33
147	Role of Uncontrolled HIV RNA Level and Immunodeficiency in the Occurrence of Malignancy in HIVâ€‹Infected Patients during the Combination Antiretroviral Therapy Era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clinical Infectious Diseases, 2009, 49, 1109-1116.	5.8	100
148	Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. Journal of Antimicrobial Chemotherapy, 2009, 63, 1251-1255.	3.0	33
149	A new endpoint definition improved clinical relevance and statistical power in a vaccine trial. Journal of Clinical Epidemiology, 2009, 62, 1054-1061.	5.0	11
150	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. Aids, 2009, 23, 1743-1753.	2.2	200
151	Ribavirin Plasma Concentration Predicts Sustained Virological Response to Peginterferon Alfa 2a Plus Ribavirin in Previously Treated HCV-HIVâ€"Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 428-430.	2.1	8
152	Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC Medical Research Methodology, 2008, 8, 68.	3.1	4
153	The Role of Mannose-Binding Lectin in Susceptibility to Infection in Preterm Neonates. Pediatric Research, 2008, 63, 680-685.	2.3	78
154	Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. Aids, 2008, 22, 1417-1423.	2.2	92
155	Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. Aids, 2008, 22, 395-402.	2.2	188
156	Pediatric Human Immunodeficiency Virus Infection and Circulating IgD$^+$ Memory B Cells. Journal of Infectious Diseases, 2008, 198, 481-485.	4.0	24
157	Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant Recipients. Journal of Clinical Microbiology, 2008, 46, 493-498.	3.9	56
158	Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. Aids, 2008, 22, 457-468.	2.2	80
159	Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, CÃ´te d'Ivoire. Aids, 2008, 22, 1815-1820.	2.2	110
160	Immunological Monitoring of Calcineurin Inhibitors for Predicting Cytomegalovirus Infection in Kidney Transplant Recipients. Transplantation, 2008, 86, 1060-1067.	1.0	10
161	Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?. Aids, 2008, 22, 996-997.	2.2	2
162	Virological Response to Darunavir/Ritonavir-Based Regimens in Antiretroviral-Experienced Patients (PREDIZISTA Study). Antiviral Therapy, 2008, 13, 271-280.	1.0	25

#	Article	IF	Citations
163	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	27.0	1,393
164	Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysisâ€. International Journal of Epidemiology, 2007, 36, 1009-1021.	1.9	207
165	Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir-Ritonavir-Based Regimens in Antiretroviral-Experienced Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 1473-1480.	3.2	26
166	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids, 2007, 21, 1185-1197.	2.2	264
167	Pravastatin in HIV-Infected Patients Treated with Protease Inhibitors: A Placebo-Controlled Randomized Study. HIV Clinical Trials, 2007, 8, 53-60.	2.0	22
168	Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet, The, 2007, 369, 115-122.	13.7	439
169	Robustness of the linear mixed model to misspecified error distribution. Computational Statistics and Data Analysis, 2007, 51, 5142-5154.	1.2	162
170	Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Medicine, 2007, 33, 148-152.	8.2	104
171	Primary Resistance to Enfuvirtide (T20) in recently HIV-1 Infected, Antiretroviral-Naive Patients from the ANRS Aquitaine Cohort. Antiviral Therapy, 2007, 12, 559-562.	1.0	24
172	Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 124, 3-9.	1.1	26
173	Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. Journal of Clinical Virology, 2006, 36, 95-99.	3.1	6
174	Behavioral audiometry: Validity of audiometric measurements obtained using the â€œDelaroche protocolâ€•in babies aged 4â€"18 months suffering from bilateral sensorineural hearing loss. International Journal of Pediatric Otorhinolaryngology, 2006, 70, 993-1002.	1.0	11
175	Estimation of dynamical model parameters taking into account undetectable marker values. BMC Medical Research Methodology, 2006, 6, 38.	3.1	40
176	CD4 Natural History and Informative Censoring in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 380-381.	2.1	2
177	Factors Associated with the Occurrence of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Aquitaine Cohort, France. Clinical Infectious Diseases, 2006, 42, 411-417.	5.8	58
178	Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antiviral Therapy, 2006, 11, 343-50.	1.0	4
179	Change in T-Lymphocyte Count after Initiation of Highly Active Antiretroviral Therapy in HIV-Infected Patients with History of <i>Mycobacterium Avium</i> Complex Infection. Antiviral Therapy, 2006, 11, 343-350.	1.0	9
180	Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 Ã— 106 cells/l. Aids, 2005, 19, 53-61.	2.2	36

#	ARTICLE	IF	CITATIONS
181	A multistate approach for estimating the incidence of human immunodeficiency virus by using data from a prevalent cohort study. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 739-752.	1.0	15
182	Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/µl? Impact on immunovirological parameters. Journal of Medical Virology, 2005, 77, 164-172.	5.0	16
183	Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection. Statistics in Medicine, 2005, 24, 65-82.	1.6	76
184	Occurrence of Listeria spp. in Effluents of French Urban Wastewater Treatment Plants. Applied and Environmental Microbiology, 2005, 71, 7562-7566.	3.1	55
185	Treatment of dyslipidaemia in HIV-infected persons. Expert Opinion on Pharmacotherapy, 2005, 6, 1619-1645.	1.8	11
186	Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitaine Cohort, 1999–2004. Aids, 2005, 19, 729-731.	2.2	34
187	SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS. Journal of Hepatology, 2005, 42, 615-624.	3.7	357
188	Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral Therapy, 2005, 10, 811-23.	1.0	43
189	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	1.0	103
190	Mixed models for longitudinal left-censored repeated measures. Computer Methods and Programs in Biomedicine, 2004, 74, 255-260.	4.7	94
191	Behavioral audiometry: protocols for measuring hearing thresholds in babies aged 4–18 months. International Journal of Pediatric Otorhinolaryngology, 2004, 68, 1233-1243.	1.0	18
192	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. American Journal of Clinical Pathology, 2003, 119, 414-423.	0.7	51
193	Bivariate Longitudinal Model For The Analysis Of The Evolution Of Hiv Rna And Cd4 Cell Count In Hiv Infection Taking Into Account Left Censoring Of Hiv Rna Measures. Journal of Biopharmaceutical Statistics, 2003, 13, 271-282.	0.8	17
194	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-1193.	2.2	770
195	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	27.0	1,560
196	Time-Updated CD4+ T Lymphocyte Count and HIV RNA as Major Markers of Disease Progression in Naive HIV-1-Infected Patients Treated With a Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 380-386.	2.1	18
197	Analysis of Undetectable HIV RNA Using Survival Analysis: Results Must Be Interpreted Carefully. HIV Clinical Trials, 2003, 4, 417-420.	2.0	1
198	Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-93.	2.2	335

#	Article	IF	Citations
199	Bone Marrow Histopathologic and Molecular Staging in Epidermotropic T-Cell Lymphomas. American Journal of Clinical Pathology, 2003, 119, 0-0.	0.7	0
200	Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine, 2002, 34, 55-63.	3.8	118
201	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. International Journal of Epidemiology, 2002, 31, 951-958.	1.9	64
202	Predictors of Longâ€Term Increase in CD4+Cell Counts in Human Immunodeficiency Virusâ€"Infected Patients Receiving a Protease Inhibitorâ€"Containing Antiretroviral Regimen. Journal of Infectious Diseases, 2002, 185, 471-480.	4.0	114
203	Bivariate linear mixed models using SAS proc MIXED. Computer Methods and Programs in Biomedicine, 2002, 69, 249-256.	4.7	93
204	Weight Loss and Body Mass Index as Predictors of HIV Disease Progression to AIDS in Adults. Aquitaine Cohort, France, 1985â€"1997. Journal of the American College of Nutrition, 2001, 20, 609-615.	1.8	43
205	Evidence that an Identical T Cell Clone in Skin and Peripheral Blood Lymphocytes is an Independent Prognostic Factor in Primary Cutaneous T Cell Lymphomas. Journal of Investigative Dermatology, 2001, 117, 920-926.	0.7	74
206	Efavirenz-associated breast hypertrophy in HIV-infected patients. Aids, 2001, 15, 126-129.	2.2	30
207	Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Aids, 2000, 14, 971-978.	2.2	80
208	Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999. Clinical Infectious Diseases, 2000, 31, 1482-1487.	5.8	152
209	Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome. European Journal of Internal Medicine, 2000, 11, 257-263.	2.2	15
210	Dataâ€driven sparse partial least squares. Statistical Analysis and Data Mining, 0, , .	2.8	2
211	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. ELife, 0, 11, .	6.0	7